India's pricing authority demands Rs700 million from Cipla
This article was originally published in Scrip
Executive Summary
Cipla says that it has received "fresh" notices from India's National Pharmaceutical Pricing Authority (NPPA) demanding Rs731.6 million ($16.3 million). The government alleges that many pharmaceutical companies, including Cipla, have over-charged for certain drugs.